Extending patient survival with next-generation treatment combinations.

Development Pipeline

We are advancing a pipeline of innovative immuno-oncology programs.

Coherus is developing a diversified pipeline of immuno-oncology therapeutics that can be part of next-generation treatment combinations to extend survival for patients with cancer across difficult-to-treat tumor types. Our pipeline programs have distinct targets designed to inhibit immune suppressive mechanisms in the tumor microenvironment with the goal of delivering powerful anti-tumor activity and, ultimately, transforming outcomes for patients. Our pipeline includes a range of novel preclinical and clinical-stage immuno-oncology programs currently in development.

Coherus-led Immuno-oncology Programs
Program
Description
Indication
Stage
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
  • Approved
LOQTORZI®
(toripalimab-tpzi)*
Anti-PD-1 monoclonal antibody
Nasopharyngeal Carcinoma

(IL combo with chemo)
Approved
Nasopharyngeal Carcinoma

(2L/3L monotherapy)
Approved
Approved
Approved
Casdozokitug
IL-27 antagonist monoclonal antibody
Hepatocellular Carcinoma
Phase 2
Non-Small Cell Lung Cancer
Phase 2
Phase 2
Phase 2
CHS-114
Anti-CCR8 monoclonal antibody
Solid Tumors

(including head & neck cancer)
Phase 1
Phase 1
CHS-1000
Anti-ILT4 monoclonal antibody
Solid Tumors
(combined with toripalimab)
Pre Clin.
Pre Clin.

* Coherus owns the rights to LOQTORZI® in the United States and Canada.

Licensed Immuno-oncology Programs
Program
Description
Indication
Stage
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
  • Approved
NZV930^
Anti-CD73 monoclonal antibody
Solid Tumors
Phase 1
Phase 1
GSK4381562^^
Anti-PVRIG monoclonal antibody
Solid Tumors
Phase 1
Phase 1

^ Coherus has licensed worldwide rights to Novartis.
^^ Coherus has licensed worldwide rights to GSK.

Learn more about toripalimab, our next generation anti-PD-1 monoclonal antibody.

See Toripalimab – PD-1 Inhibitor